Lorenz H. Trumper
Advanced in Chromosome 12p Deletion

Lorenz H. Trumper

Robert Koch Str. 40, 
Goettingen, NI, DE 
Advanced in Chromosome 12p Deletion
Robert Koch Str. 40, 
Goettingen, NI, DE 
OverviewLocationsClinical Research

Overview

Lorenz Trumper practices in Goettingen, Germany. Mr. Trumper is rated as an Advanced expert by MediFind in the treatment of Chromosome 12p Deletion. His top areas of expertise are Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, B-Cell Lymphoma, Burkitt Lymphoma, and Bone Marrow Transplant.

His clinical research consists of co-authoring 158 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Chromosome 12p Deletion.

Gender
Male

Locations

Robert Koch Str. 40, Goettingen, NI 37075, Germany
Other Locations
Robert Koch Str. 42, Goettingen, NI 37077, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Obinutuzumab in Marginal Zone Lymphoma (OLYMP-1)
Obinutuzumab in Marginal Zone Lymphoma (OLYMP-1)
Enrollment Status: Active_not_recruiting
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: Obinutuzumab
Study Phase: Phase 2
Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug
Study Drugs: Romidepsin, CHOP
Study Phase: Phase 3
Subcutaneous Rituximab and Intravenous Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients (Slow Go) With Aggressive CD20-positive B-cell
Subcutaneous Rituximab and Intravenous Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients (Slow Go) With Aggressive CD20-positive B-cell
Enrollment Status: Completed
Publish Date: December 31, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

158 Total Publications

Subtyping Burkitt Lymphoma by DNA Methylation.
Subtyping Burkitt Lymphoma by DNA Methylation.
Journal: Genes, chromosomes & cancer
Published: February 06, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Trumper's expertise for a condition
ConditionClose
View All 12 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile